Shire seeks US FDA OK to make first med at Covington

By Gareth Macdonald

- Last updated on GMT

Gettyimages/media point inc
Gettyimages/media point inc

Related tags U.s. securities and exchange commission

Shire plc has asked the US FDA for permission to make its first product at its facility in Covington, Georgia.

Ireland-domiciled Shire announced it had sought agency permission to produce Gammagard Liquid – a plasma-derived antibody product used to treat primary humoral immunodeficiency (PI) - last month.

Matt Walker, head of technical operations for Shire, said, “We are pleased to have filed the Georgia site and look forward to working with the FDA to seek approval for manufacturing in 2018​.”

The firm also announced its intention to seek permission to make a second product this year.

Shire acquired the Covington facility when it bought Baxalta in 2016​.

In a subsequent US Securities and Exchange Commission (SEC) filing, the firm stated the facility would support growth of its plasma-based treatments.

At present, Shire employs 900 people in Covington. However, the firm said it intends to “ramp up hiring in 2018 to fill roles in manufacturing, quality, engineering, maintenance, utilities, warehouse and a variety of support and facility roles​.”

In addition, Shire said that its subsidiary BioLife Plasma Services would further expand its plasma collection network in Georgia and throughout the US.

Related topics Downstream Processing Facilities

Related news

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more